UNSPSC 51413906: Iproxamine

This classification denotes a vasodilating agent with the molecular formula C18H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier URR853YLZA, chemically known as [4-(2-dimethylaminoethyloxy)-2-methyl-5-propan-2-ylphenyl] propan-2-yl carbonate but generally known as iproxamine, which bears US NIH Compound Identifier 172983. Most nations schedule iproxamine under HS 29221980 and SITC 51461. As of Q4 2014, IPROXAMINE remains the US FDA Preferred Term for this commodity.

Iproxamine bears US NLM identifiers UMLS ID C1881263 and NCI Concept Code C65956. SMILES: CC1=CC(=C(C=C1OC(=O)OC(C)C)C(C)C)OCCN(C)C.

UNSPSC 51413906 Iproxamine, a Commodity code, designates a single pharmaceutical product actively procured by state and local emergency medical and healthcare benefit organizations. State and local buyers under this code are acquiring advanced life support medications and pharmacy benefit program inputs — specifically emergency injectable medications for fire rescue and EMS operations, as well as generic pharmaceuticals and over-the-counter products for state health plans and cooperative purchasing networks. The issuing bodies are municipal fire departments and city procurement offices, state health and human services agencies, and multistate cooperative purchasing alliances administering contracts on behalf of participating state and local government members.

Recent solicitations span Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026, requesting advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000; the contract includes a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation and requires OSHA-compliant Safety Data Sheets and WCAG 2.2 Level AA accessibility documentation. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to assess vendor capability for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and wholesaler channels, reflecting the state's exploration of cost-management and efficiency strategies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness and 25 percent combined on fixed pricing, compliance, EDI capability, and administrative fee agreement. Vendors must maintain two-of-three relationships with authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, and carry professional liability and network security insurance coverage of $2,000,000 each.